acetylcysteine has been researched along with everolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bieri, M; Farkas, A; Koestner, SC; Ligeti, N; Meier, B; Mohacsi, PJ; Oroszlán, M | 1 |
1 review(s) available for acetylcysteine and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for acetylcysteine and everolimus
| Article | Year |
|---|---|
Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant.
Topics: Acetylcysteine; Cadherins; Cell Division; Cell Membrane Permeability; Endothelium, Vascular; Everolimus; Free Radical Scavengers; Humans; Oxidative Stress; Permeability; Signal Transduction; Sirolimus; Umbilical Veins | 2008 |